@article{f0b582996dc948f991545dc0003ac9d4,
title = "Lipid Metabolism Gets in a JAML during Kidney Disease",
abstract = "It is still unclear if the ability of key regulators of actin cytoskeletal remodeling to influence lipid metabolism contributes to kidney injury. In this issue of Cell Metabolism, Fu et al. (2020) show that junctional adhesion molecule-like (JAML) is a novel mediator of glomerular disease progression while suggesting a direct link between defects in cell adhesion and lipotoxicity.",
author = "Alessia Fornoni and Sandra Merscher",
note = "Funding Information: A.F. and S.M. are supported by NIH grants R01DK117599 , R01DK104753 , and R01CA227493 , and by Boehringer Ingelheim . A.F. is supported by NIH grants U54DK083912 , UM1DK100846 , U01DK116101 , and UL1TR000460 ( Miami Clinical Translational Science Institute , Translational Science Institute , from the National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities ). We give a special thanks to the Katz family for their continuous support. Figure was created with https://biorender.com/ . Funding Information: A.F. and S.M. are supported by NIH grants R01DK117599, R01DK104753, and R01CA227493, and by Boehringer Ingelheim. A.F. is supported by NIH grants U54DK083912, UM1DK100846, U01DK116101, and UL1TR000460 (Miami Clinical Translational Science Institute, Translational Science Institute, from the National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities). We give a special thanks to the Katz family for their continuous support. Figure was created with https://biorender.com/. A.F. and S.M. are inventors on pending or issued patents (PCT/US11/56272, PCT/US12/62594, PCT/US2019/041730, PCT/US2019/032215, PCT/US13/36484, and PCT 62/674,897) aimed at diagnosing or treating proteinuric kidney diseases. They stand to gain royalties from their future commercialization of these patents. A.F. is Vice President of L&F Health LLC and is a consultant for ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc. has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin from L&F Research for the treatment of kidney disease. S.M. holds indirect equity interest in, and potential royalty from, ZyVersa Therapeutics, Inc. by virtue of assignment and licensure of a patent estate. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = dec,
day = "1",
doi = "10.1016/j.cmet.2020.11.002",
language = "English (US)",
volume = "32",
pages = "903--905",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "6",
}